The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple myeloma (RRMM) patients (Pts): Analysis of pooled data.

B. G. Durie

Consultant or Advisory Role - Celgene; Millennium; Onyx

G. Morgan

Consultant or Advisory Role - Celgene; Janssen Oncology; Novartis

Honoraria - Celgene; Janssen Oncology; Novartis

J. F. San-Miguel

Consultant or Advisory Role - Celgene

R. Z. Orlowski

Consultant or Advisory Role - Celgene; Millennium

Research Funding - Celgene; Millennium

S. Lonial

Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx

Research Funding - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx

R. Niesvizky

Consultant or Advisory Role - Celgene; Millennium; Onyx

Honoraria - Celgene; Millennium; Novartis

Research Funding - Celgene; Millennium; Onyx

Z. Yu

Employment or Leadership Position - Celgene

K. C. Anderson

Employment or Leadership Position - Acetylon Pharmaceuticals

Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx

Stock Ownership - Acetylon Pharmaceuticals

Honoraria - Celgene; Merck; Millennium; Novartis; Onyx

Research Funding - Celgene; Merck; Millennium